FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved survival rates for patients.

Omitting carboplatin could be an efficacious de-escalated neoadjuvant strategy in the presence of dual HER2 blockade for patients with HER2-positive early breast cancer,” said Kun Wang, MD, PhD.

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, discusses how Emrelis fits into the current antibody-drug conjugate landscape and what distinguishes its approach in biomarker-driven ...

Oncolytics Biotech reveals promising survival data for pelareorep, an innovative immunotherapy, showing significant benefits ...

The Cancer Immunotherapy market, valued at USD 220.94 billion in 2024, is expected to register robust revenue CAGR of 13.6%.

DelveInsight’s, “Glioma Pipeline Insight, 2025” report provides comprehensive insights about 180+ companies and 200+ pipeline ...

The study will compare neladalkib to Genentech's ALK inhibitor Alecensa in patients who've had no prior systemic treatment.

CAMBRIDGE, MA, USA I July 21, 2025 I Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on ...

A Food and Drug Administration expert panel has reignited a debate over whether hormone therapy should be used to treat ...

What makes the human brain distinctive? A new study published July 21 in Cell identifies two genes linked to human brain ...

Despite some near-term revenue growth, HRTX's future is uncertain. Click here to find out why HRTX stock is a Hold.

The Precision Era of medicine is arriving in Asia Pacific, driven by the arrival of a critical mass of innovative ...